Advanced search
1 file | 14.54 KB

Cost-effectiveness of [18F]FET for therapy assessment of temozolomide for patients with glioblastoma in a Belgian healthcare setting

Tristan Baguet (UGent) , Jeroen Verhoeven (UGent) , Filip De Vos (UGent) and Ingeborg Goethals (UGent)
(2018) NEURO-ONCOLOGY. 20(suppl. 3).
Author
Organization

Downloads

  • Abstract EANO 2018.docx
    • full text
    • |
    • open access
    • |
    • Word
    • |
    • 14.54 KB

Citation

Please use this url to cite or link to this publication:

Chicago
Baguet, Tristan, Jeroen Verhoeven, Filip De Vos, and Ingeborg Goethals. 2018. “Cost-effectiveness of [18F]FET for Therapy Assessment of Temozolomide for Patients with Glioblastoma in a Belgian Healthcare Setting.” In Neuro-oncology. Vol. 20.
APA
Baguet, Tristan, Verhoeven, J., De Vos, F., & Goethals, I. (2018). Cost-effectiveness of [18F]FET for therapy assessment of temozolomide for patients with glioblastoma in a Belgian healthcare setting. NEURO-ONCOLOGY (Vol. 20). Presented at the 13th Meeting of the European Association of Neuro-Oncology (EANO meeting 2018).
Vancouver
1.
Baguet T, Verhoeven J, De Vos F, Goethals I. Cost-effectiveness of [18F]FET for therapy assessment of temozolomide for patients with glioblastoma in a Belgian healthcare setting. NEURO-ONCOLOGY. 2018.
MLA
Baguet, Tristan, Jeroen Verhoeven, Filip De Vos, et al. “Cost-effectiveness of [18F]FET for Therapy Assessment of Temozolomide for Patients with Glioblastoma in a Belgian Healthcare Setting.” Neuro-oncology. Vol. 20. 2018. Print.
@inproceedings{8578181,
  author       = {Baguet, Tristan and Verhoeven, Jeroen and De Vos, Filip and Goethals, Ingeborg},
  booktitle    = {NEURO-ONCOLOGY},
  issn         = {1522-8517},
  language     = {eng},
  location     = {Stockholm, Sweden},
  number       = {suppl. 3},
  title        = {Cost-effectiveness of [18F]FET for therapy assessment of temozolomide for patients with glioblastoma in a Belgian healthcare setting},
  volume       = {20},
  year         = {2018},
}